The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The company is excluding data from the affected sites to maintain the study's integrity
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Subscribe To Our Newsletter & Stay Updated
